|The full article is available to subscribers||Subscriber Login|
The FDA has approved the use of a transcutaneous electrical nerve stimulation device (Cefaly – Cefaly Technology) for prevention of episodic migraine in patients ≥18 years old. The first device to be approved in the US for migraine prevention, it is available in Canada and Europe for treatment and prevention of migraines. A transcranial magnetic stimulation device (SpringTMS - eNeura Therapeutics) recently approved by the FDA for treatment of migraine preceded by aura will be reviewed in a future issue.
THE DEVICE — The Cefaly device consists of a battery-operated electrical pulse generator and a selfadhesive electrode. The patient applies the electrode to the middle of the forehead and lowers a headband containing the electrical pulse generator over the forehead to engage a pin located on the electrode. Pressing a button on the band generates a pulsed electric current that stimulates the... more
- Approximate cost according to the manufacturer.
- J Schoenen et al. Migraine prevention with a supraorbital transcutaneous stimulator : a randomized controlled trial. Neurology 2013; 80:697.
- D Magis et al. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain 2013; 14:95.